Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
742 | 3034 | 41.4 | 83% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
869 | 10864 | LIPODYSTROPHY//HIV ASSOCIATED NEPHROPATHY//LIPOATROPHY |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | LIPODYSTROPHY | Author keyword | 286 | 50% | 14% | 410 |
2 | LIPOATROPHY | Author keyword | 79 | 52% | 4% | 108 |
3 | PROGRAM NUTR METAB | Address | 46 | 52% | 2% | 63 |
4 | HIV ASSOCIATED LIPODYSTROPHY SYNDROME | Author keyword | 41 | 85% | 1% | 22 |
5 | FAT REDISTRIBUTION | Author keyword | 30 | 68% | 1% | 26 |
6 | LIPODYSTROPHY SYNDROME | Author keyword | 27 | 76% | 1% | 19 |
7 | LIPOHYPERTROPHY | Author keyword | 25 | 58% | 1% | 29 |
8 | HIV LIPODYSTROPHY | Author keyword | 23 | 72% | 1% | 18 |
9 | HIV ASSOCIATED LIPODYSTROPHY | Author keyword | 17 | 79% | 0% | 11 |
10 | BUFFALO HUMP | Author keyword | 17 | 100% | 0% | 8 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | LIPODYSTROPHY | 286 | 50% | 14% | 410 | Search LIPODYSTROPHY | Search LIPODYSTROPHY |
2 | LIPOATROPHY | 79 | 52% | 4% | 108 | Search LIPOATROPHY | Search LIPOATROPHY |
3 | HIV ASSOCIATED LIPODYSTROPHY SYNDROME | 41 | 85% | 1% | 22 | Search HIV+ASSOCIATED+LIPODYSTROPHY+SYNDROME | Search HIV+ASSOCIATED+LIPODYSTROPHY+SYNDROME |
4 | FAT REDISTRIBUTION | 30 | 68% | 1% | 26 | Search FAT+REDISTRIBUTION | Search FAT+REDISTRIBUTION |
5 | LIPODYSTROPHY SYNDROME | 27 | 76% | 1% | 19 | Search LIPODYSTROPHY+SYNDROME | Search LIPODYSTROPHY+SYNDROME |
6 | LIPOHYPERTROPHY | 25 | 58% | 1% | 29 | Search LIPOHYPERTROPHY | Search LIPOHYPERTROPHY |
7 | HIV LIPODYSTROPHY | 23 | 72% | 1% | 18 | Search HIV+LIPODYSTROPHY | Search HIV+LIPODYSTROPHY |
8 | HIV ASSOCIATED LIPODYSTROPHY | 17 | 79% | 0% | 11 | Search HIV+ASSOCIATED+LIPODYSTROPHY | Search HIV+ASSOCIATED+LIPODYSTROPHY |
9 | BUFFALO HUMP | 17 | 100% | 0% | 8 | Search BUFFALO+HUMP | Search BUFFALO+HUMP |
10 | FAT MASS RATIO | 11 | 100% | 0% | 6 | Search FAT+MASS+RATIO | Search FAT+MASS+RATIO |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | LIPODYSTROPHY | 263 | 41% | 16% | 500 |
2 | FAT REDISTRIBUTION | 163 | 86% | 3% | 84 |
3 | PERIPHERAL LIPODYSTROPHY | 143 | 73% | 4% | 110 |
4 | LIPODYSTROPHY SYNDROME | 124 | 69% | 4% | 107 |
5 | PROTEASE INHIBITORS | 102 | 14% | 23% | 697 |
6 | INHIBITOR ASSOCIATED LIPODYSTROPHY | 71 | 76% | 2% | 50 |
7 | FASTING HYPERINSULINEMIA | 48 | 77% | 1% | 33 |
8 | REVERSE TRANSCRIPTASE INHIBITORS | 47 | 13% | 11% | 340 |
9 | LIPOATROPHY | 47 | 38% | 3% | 97 |
10 | METABOLIC ABNORMALITIES | 43 | 31% | 4% | 114 |
Journals |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | HIV MEDICINE | 15 | 12% | 4% | 117 |
2 | HIV CLINICAL TRIALS | 6 | 11% | 2% | 53 |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Stimulating High Impact HIV-Related Cardiovascular Research Recommendations From a Multidisciplinary NHLBI Working Group on HIV-Related Heart, Lung, and Blood Disease | 2015 | 2 | 42 | 79% |
HIV infection and cardiovascular disease | 2014 | 9 | 75 | 77% |
The end of AIDS: HIV infection as a chronic disease | 2013 | 99 | 82 | 26% |
Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review | 2013 | 24 | 35 | 74% |
Update on metabolic issues in HIV patients | 2014 | 8 | 59 | 63% |
Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients | 2014 | 7 | 82 | 66% |
Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group | 2003 | 326 | 114 | 51% |
HIV-associated lipodystrophy: from fat injury to premature aging | 2010 | 61 | 88 | 63% |
Metabolic disease in HIV infection | 2013 | 15 | 124 | 77% |
HIV Infection, Inflammation, Immunosenescence, and Aging | 2011 | 262 | 87 | 13% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | PROGRAM NUTR METAB | 46 | 52% | 2.1% | 63 |
2 | AHOD | 11 | 100% | 0.2% | 6 |
3 | CPCRA | 8 | 100% | 0.2% | 5 |
4 | HIV IMMUNOL INFECT DIS CLIN SERV UNIT | 7 | 31% | 0.7% | 20 |
5 | TRANSLAT METAB UNIT | 7 | 39% | 0.5% | 14 |
6 | EUROSIDA | 6 | 80% | 0.1% | 4 |
7 | RED INVEST SIDA RIS | 6 | 80% | 0.1% | 4 |
8 | HIV METAB CLIN | 6 | 71% | 0.2% | 5 |
9 | COPENHAGEN HIV PROGRAMME CHIP | 6 | 53% | 0.3% | 8 |
10 | NUTR INFECT UNIT | 6 | 39% | 0.4% | 12 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000149945 | HIV WASTING//HIV WASTING SYNDROME//WASTING |
2 | 0.0000142739 | MITOCHONDRIAL TOXICITY//DISTAL SENSORY POLYNEUROPATHY//ANTIRETROVIRAL TOXIC NEUROPATHY |
3 | 0.0000137569 | HIV MOL GRP//MED INT MED INFECT DIS//BODY COMPOSIT ANAL |
4 | 0.0000119647 | HIV RELATED PULMONARY HYPERTENSION//HIV ASSOCIATED CARDIOMYOPATHY//CA2M |
5 | 0.0000114150 | ROYAL FREE HIV MED//CD4 CELL COUNT//X BICHAT MED |
6 | 0.0000099000 | VIETNAM EVIDENCE HLTH POLICY PROJECT//CELL PHONE INTERVENTION//NON AIDS RELATED MORTALITY |
7 | 0.0000080992 | NELFINAVIR//SAQUINAVIR NO//ANTIRETROVIRALL THERAPY |
8 | 0.0000079621 | CONGENITAL GENERALIZED LIPODYSTROPHY//SEIPIN//BSCL2 |
9 | 0.0000067734 | ATAZANAVIR//RITONAVIR//LOPINAVIR |
10 | 0.0000061920 | 1200 N STATE ST//ADRENAL RESERVE//ADRENOCORTICAL DYSFUNCTION |